CN

CN EN

 

Newsroom

Company News

Home > Newsroom > Company News
05/06/2018
CMAB Reaches Strategic Partnership with GeneQuantum

SUZHOU, June 5, 2018 – CMAB Biopharma Inc. (CMAB), a full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products, today announced a strategic partnership with GeneQuantum Healthcare (Suzhou) Co., Ltd., a high-tech company focused on the research and development of innovative Bio-therapeutics, especially Antibody Drug Conjugate (ADC) in anti-cancer agents.


As part of this agreement, the two companies will leverage their respective expertise and capabilities in the research, development and manufacture of antibody-drug conjugates to accelerate the go-to-market speed of GeneQuantum's innovative drugs, and provide more efficient and safer medicines for cancer patients worldwide.


As a biotechnology company focusing on biopharmaceutical development, GeneQuantum has established an innovative development platform for bio-conjugation drugs.


"In choosing this partner, we highly valued CMAB's development capabilities, production platform and expert team in the field of antibody drugs," said Dr. Qin Gang, CEO of GeneQuantum. "CMAB is a perfect match for us, with its outstanding CDMO capabilities and experienced and resourceful team. The partnership will free us to focus more on drug R&D. As neighbors in the same city, we look forward to strengthening our cooperation throughout the entire life cycle of innovative drugs."


Located in Suzhou's BioBAY Park, CMAB provides one-stop services, from cell line establishment, process development, test methods, GMP production, to declaration in and out of China, for both domestic and international biopharmaceutical R&D companies. CMAB strictly followsthe quality standards of international and domestic regulations, including those of the China Food & Drug Administration, US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards. Currently,  CMAB focuses on providing pre-clinical and early-stage clinical (Phase I/II) products for Chinese and international clients.


"The partnership with GeneQuantum demonstrates CMAB's expertise and experience in CDMO," said Mr. Qibin Liang, President of CMAB. "It is also a good example of how the CDMO industry can help optimize resource allocation and support biopharmaceutical companies to develop innovative products. As a pure CDMO provider in China, CMAB's one-stop service with 'co-development and customized manufacturing' can provide high-quality, high-efficiency and cost-effective Drug Substance/Drug Products development and production services to GeneQuantum and other biological R&D companies, and speed up the whole process from drug concept to clinical development."


Follow us

Site Map|Privacy Policy|Terms of Use|Contact

Copyright © 2018 CMAB BioPharma (Suzhou) Inc.   苏ICP备18005502号